Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT05016895 |
Other study ID # |
1743615 |
Secondary ID |
|
Status |
Recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
August 27, 2021 |
Est. completion date |
February 28, 2024 |
Study information
Verified date |
February 2024 |
Source |
FHI 360 |
Contact |
Lisa Dulli, PhD |
Phone |
9193213542 |
Email |
ldulli[@]fhi360.org |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
REACH2 is a three-year implementation research study designed to examine the implementation
through a mass drug administration platform of bi-annual single-dose azithromycin to reduce
child mortality among children ages 1 to 11 months who reside in high child mortality
settings.
Description:
The aim of the study is to provide the government of Côte d'Ivoire and other stakeholders the
information needed to understand what is required to bring bi-annual mass drug administration
(MDA) of single-dose azithromycin for children ages 1 to 11 months in high child mortality
settings to scale using the existing MDA platform used for trachoma and other neglected
tropical diseases.
Design: The serial cross-sectional study will be carried out in 19 health districts in
coordination with the trachoma MDAs over the course of three years. The intervention under
study will involve a public health campaign of bi-annual distribution of single-dose
azithromycin, including:
1. Expanded coverage with azithromycin during annual trachoma MDAs to children 1-5 months
of age when delivered at the same time as the annual trachoma MDA, which already covers
children 6-11 months, followed by
2. Stand-alone MDAs targeting children 1 to 11 months delivered at the approximately
6-month interval between annual trachoma MDAs, or bi-annually in areas where the annual
trachoma MDAs are phased out.
To study scale up of these intervention activities, the investigators will systematically
collect data, guided by the Reach, Effectiveness, Adoption, Implementation and Maintenance
(RE-AIM) implementation science framework. Data collection activities will involve:
1. Analyses of routine monitoring, process, and adverse drug reaction data from the
trachoma MDA platform into which the REACH activities are being integrated
2. Periodic, cross-sectional, post-MDA surveys to verify coverage and examine exposure to
project information/messaging
3. Qualitative data collection through in-depth interviews (IDI) and/or focus group
discussions (FGD) with parents or primary caregivers of children ages 1 to 11 months in
the 19 health districts, and district-level MDA implementers to explore issues of
acceptability, communication, challenges and areas for improvement in implementation.
Further, after the first round of the annual trachoma MDA scheduled to take place in July
2021, a round of focus groups will be carried out with parents of children ages 1-11 months
and local implementers to inform message development for the public health campaign.